Status and phase
Conditions
Treatments
About
Hospital acquired acute kidney injury is an important negative outcome predictor for hospitalized patients. Uremic toxins accumulated after a given renal insult. Some of these uremic toxins are protein bound and may accumulated after renal impairment, owing to both impaired filtration, and inflammation. Recent animal studies have reported that accumulation of uremic toxins, namely indoxyl sulfate and p-cresol, would down regulate endothelial progenitor cells and in turn affect renal recovery. Elimination of these protein bound uremic toxins with an activated charcoal would help restore endothelial function. We will conduct a double blinded randomized placebo controlled trial, which aims to determine that if oral activated charcoal will retard progression of AKI. Also, a panel of markers for endothelial function will also be determined.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
This is a prospective randomized placebo controlled trial. All patients admitted to participating centers with newly diagnosed acute kidney injury (AKI) will be screened for eligibility. The diagnosis of AKI will be determined and staged according to the KIGO-AKI Guideline.11 The inclusion criteria include:
Patients with the following conditions will be excluded:
Primary purpose
Allocation
Interventional model
Masking
206 participants in 2 patient groups
Loading...
Central trial contact
KWAN-DUN WU; Tao-Min Huang
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal